This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elias, D. Articles by Lasser, P. Search for Related Content PubMed PubMed Citation Articles by Elias, D. Articles by Lasser, P.

Treatment of Peritoneal Carcinomatosis From Colorectal Cancer: Impact of Complete Cytoreductive Surgery and Difficulties in Conducting Randomized Trials

From the Departments of Surgery, Medical Oncology, and Statistics, Gustave Roussy Institute, Villejuif, France (DE, LS, EB, MP, OB, PL); and the Paoli-Calmette Institute, Marseille, France (J-RD).

Correspondence: Address correspondence and reprint requests to: Dominique Elias, MD, PhD, Service de Chirurgie Carcinologique, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France; Fax: 33-1-42-11-52-56; E-mail: elias{at}igr.fr

Background: Colorectal peritoneal carcinomatosis (PC) is a frequent and very lethal event. However, cure may be possible with maximal cytoreductive surgery associated with early postoperative intraperitoneal chemotherapy (EPIC).

Methods: Between 1996 and 2000, we conducted a two-center prospective randomized trial comparing EPIC plus systemic chemotherapy with systemic chemotherapy alone, both after complete cytoreductive surgery of colorectal PC. Only 35 patients could be included among the 90 who were theoretically required, mainly because of patient dissatisfaction with the inclusion criteria. For this reason, the trial was stopped prematurely.

Results: Analysis of these 35 patients showed that complete resection of PC resulted in a 2-year survival rate of 60%—far above the classic 10% survival rate among patients with colorectal PC treated with systemic chemotherapy and symptomatic surgery. In this small series, EPIC did not demonstrate any advantage for survival.

Conclusions: This supports the use of complete cytoreductive surgery in selected patients and calls for a prospective randomized trial comparing adjuvant systemic chemotherapy with intraperitoneal chemohyperthermia after complete resection.

Key Words: Colorectal • Peritoneal carcinomatosis • Cytoreductive surgery • Intraperitoneal chemotherapy • Randomized trial

This article has been cited by other articles:

				T. D. Yan and P. H Sugarbaker An Evolving Role of Perioperative Intraperitoneal Chemotherapy After Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis Ann. Surg. Oncol., July 1, 2007; 14(7): 2171 - 2172. [Full Text] [PDF]

				T. D. Yan, J. Sim, and D. L. Morris Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Ann. Surg. Oncol., June 1, 2007; 14(6): 1807 - 1817. [Abstract] [Full Text] [PDF]

				D. Elias, D. Goere, F. Blot, V. Billard, M. Pocard, N. Kohneh-Shahri, and B. Raynard Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43{degrees}C After Compete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients Ann. Surg. Oncol., June 1, 2007; 14(6): 1818 - 1824. [Abstract] [Full Text] [PDF]

				D. Elias, E. Benizri, D. DiPietrantonio, P. Menegon, D. Malka, and B. Raynard Comparison of Two Kinds of Intraperitoneal Chemotherapy Following Complete Cytoreductive Surgery of Colorectal Peritoneal Carcinomatosis Ann. Surg. Oncol., February 1, 2007; 14(2): 509 - 514. [Abstract] [Full Text] [PDF]

				J.-H. Cheong, J. Y. Shen, C. S. Song, W. J. Hyung, J. G. Shen, S. H. Choi, and S. H. Noh Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery in Patients with Very Advanced Gastric Cancer Ann. Surg. Oncol., January 1, 2007; 14(1): 61 - 68. [Abstract] [Full Text] [PDF]

				T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma J. Clin. Oncol., August 20, 2006; 24(24): 4011 - 4019. [Abstract] [Full Text] [PDF]

				D. Elias, G. Liberale, D. Vernerey, M. Pocard, M. Ducreux, V. Boige, D. Malka, J.-P. Pignon, and P. Lasser Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect Ann. Surg. Oncol., November 1, 2005; 12(11): 900 - 909. [Abstract] [Full Text] [PDF]